"The Infinite" lands in Houston for the first U.S. show. Image courtesy of Infinity Productions

From the earliest days of our circling the planet in a tiny NASA capsule — to Elon Musk's SpaceX current commercial journeys — Houston and space travel will be forever and inexorably linked.

Fitting, then, that an unprecedented new immersive experience centered on the International Space Station (ISS) is making its U.S. debut here in Space City. "The Infinite"— a multi-sensory, interactive virtual reality experience — will zoom into Sawyer Yards on December 20 for a special, and limited, run, organizers announced.

This sprawling, 12,500-square-foot exhibition shuttles viewers into a never-before-seen perspective of life on the ISS, bringing an almost-too-real feeling of being in outer space.

Tickets are on sale now for a soft open preview period beginning on December 20; admission is $29. Tickets then jump to $36 for the full-scale limited engagement beginning on January 13, 2022.

Boasting footage shot over a period of nearly three years that created some 200 hours of high-end virtual reality scenes, the four-part immersive series documents the life of eight international astronauts inside — and outside — the International Space Station. (The outside experience promises to be an especially wild ride.) The show comes to Houston off a wildly popular Canadian run in Montreal.

Specific to this Houston launch, the show boasts new footage from the first-ever cinematic spacewalk captured in 3D — 360-degree virtual reality shot outside the International Space Station on September 12, 2021 — while offering visitors a self-directed experience aboard the ISS itself, according to a press release.

Throughout the 60-minute journey, per press materials, viewers will engage with physical objects, virtual reality, multimedia art, soundscapes, light design, and even the subtle scents of a forest, meant to evoke memories of stargazing while lying on the grass.

"The Infinite" is the brainchild of Montreal-based Infinity Experiences, a joint venture of PHI Studio and Felix & Paul Studios, and is an extension of the recent Primetime Emmy Award-winning immersive series, "Space Explorers: The ISS Experience," the largest production ever filmed in space, produced by Felix & Paul Studios in association with Time Studios.

That this show will run next year is also especially timely for Houston's space saga. Next year marks the 60th anniversary of President John F. Kennedy's famous moon-shot speech given at Rice University on September 12, 1962. That speech, with its now-legendary "we choose to go to the moon" line, galvanized the nation and propelled the U.S. into a space race that found Neil Armstrong and "Buzz" Aldrin on the moon only seven years later.

"The exploration of space and the unknown is an endless source of fascination to us," said Félix Lajeunesse, co-founder of Felix & Paul Studios and creative director of The Infinite, in a statement.

"We are thrilled to bring The Infinite to Houston — the global epicenter of human space exploration — to share this massive, fully immersive exhibition, and we look forward to virtually transporting thousands of people off the Earth to enjoy the joy and wonder of space with audiences in the U.S. This unprecedented project is made possible thanks to our partners at NASA, the ISS National Lab, international space agencies and the incredible power of virtual reality."

------

This article originally ran on CultureMap.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”

Chevron enters the lithium market with major Texas land acquisition

to market

Chevron U.S.A., a subsidiary of Houston-based energy company Chevron, has taken its first big step toward establishing a commercial-scale lithium business.

Chevron acquired leaseholds totaling about 125,000 acres in Northeast Texas and southwest Arkansas from TerraVolta Resources and East Texas Natural Resources. The acreage contains a high amount of lithium, which Chevron plans to extract from brines produced from the subsurface.

Lithium-ion batteries are used in an array of technologies, such as smartwatches, e-bikes, pacemakers, and batteries for electric vehicles, according to Chevron. The International Energy Agency estimates lithium demand could grow more than 400 percent by 2040.

“This acquisition represents a strategic investment to support energy manufacturing and expand U.S.-based critical mineral supplies,” Jeff Gustavson, president of Chevron New Energies, said in a news release. “Establishing domestic and resilient lithium supply chains is essential not only to maintaining U.S. energy leadership but also to meeting the growing demand from customers.”

Rania Yacoub, corporate business development manager at Chevron New Energies, said that amid heightening demand, lithium is “one of the world’s most sought-after natural resources.”

“Chevron is looking to help meet that demand and drive U.S. energy competitiveness by sourcing lithium domestically,” Yacoub said.

---

This article originally appeared on EnergyCapital.